1-(1H-indol-2-yl)-2-phenyl-ethan-1-one | 889472-34-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(1H-indol-2-yl)-2-phenyl-ethan-1-one
• 英文别名: 1-(1H-indol-2-yl)-2-phenylethanone
• CAS: 889472-34-8
• 化学式: C₁₆H₁₃NO
• 分子量: 235.285
• InChiKey: ZPNWJGPRXXTUNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(1H-indol-2-yl)-2-phenyl-ethan-1-one 在 吡啶 、 lithium aluminium tetrahydride 、 盐酸羟胺 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 5.0h， 生成 1-(1H-indol-2-yl)-2-phenylethylamine hydrochloride
  参考文献：
  名称：

  Benzimidazole, Benzoxazole and Benzothiazole Derivatives as 5HT2B Receptor Ligands. Synthesis and Preliminary Pharmacological Evaluation

  摘要：

  2-Phenethylbenzimidazole, 2-phenethylbenzoxazole and 2phenethylbenzothiazole derivatives were synthesized to explore the structural features of the serotonin 5-HT2B receptor antagonists. Those molecules were designed to recognize the 5-HT2B receptor and to discriminate it from the 5-HT2A and 5-HT2C subtypes. All compounds were characterized by binding affinity determination for 5-HT2A and 5-HT2C subtypes and antagonistic activity for 5-HT2B receptor in rat stomach fundus. None of the new compounds showed affinity for 5-HT2A and 5-HT2C subtypes, but some of them displayed antagonistic activity in rat stomach fundus at micromolar concentrations.

  DOI：

  10.1007/s00044-005-0125-z
• 作为产物：
  描述：

  1H-吲哚-2-羰酰氯 、 溴甲苯 在 四(三苯基膦)钯 锌 作用下， 以 乙二醇二甲醚 为溶剂， 反应 3.0h， 以26%的产率得到1-(1H-indol-2-yl)-2-phenyl-ethan-1-one
  参考文献：
  名称：

  Benzimidazole, Benzoxazole and Benzothiazole Derivatives as 5HT2B Receptor Ligands. Synthesis and Preliminary Pharmacological Evaluation

  摘要：

  2-Phenethylbenzimidazole, 2-phenethylbenzoxazole and 2phenethylbenzothiazole derivatives were synthesized to explore the structural features of the serotonin 5-HT2B receptor antagonists. Those molecules were designed to recognize the 5-HT2B receptor and to discriminate it from the 5-HT2A and 5-HT2C subtypes. All compounds were characterized by binding affinity determination for 5-HT2A and 5-HT2C subtypes and antagonistic activity for 5-HT2B receptor in rat stomach fundus. None of the new compounds showed affinity for 5-HT2A and 5-HT2C subtypes, but some of them displayed antagonistic activity in rat stomach fundus at micromolar concentrations.

  DOI：

  10.1007/s00044-005-0125-z

文献信息

• Lewis Acid Mediated Aminobenzannulation Reactions of δ-Ketoalkynes: Synthesis of 1-Aminocarbazoles and 9-Aminopyrido[1,2-<i>a</i>]indoles
  作者：Diego Facoetti、Giorgio Abbiati、Elisabetta Rossi

  DOI：10.1002/ejoc.200900039

  日期：2009.6

  2-Acyl-N-propargylindoles 1 and 2-acyl-3-propargylindoles 5 undergo aminobenzannulation reactions with pyrrolidine in the presence of an appropriate Lewis acid to give 9-aminopyrido[1,2-a]indoles 6 and 1-aminocarbazoles 7, respectively. The selection of the appropriate Lewis acid, TiCl4 or GaCl3 for 1 and InCl3 for 5, allows the domino process involving the initial formation of an enamine intermediate

  2-酰基-N-炔丙基吲哚1和2-酰基-3-炔丙基吲哚5在适当的路易斯酸存在下与吡咯烷发生氨基苯并化反应，得到9-氨基吡啶并[1,2-a]吲哚6和1-氨基咔唑7，分别。选择合适的路易斯酸，TiCl4 或 GaCl3 为 1，InCl3 为 5，允许多米诺骨牌过程涉及初始形成烯胺中间体，然后区域选择性 6-exo-dig 分子内亲核攻击不饱和的亲核末端系统（烯氨基部分的β-碳）连接到碳-碳三键。此外，还报告了有关反应机理和两种催化剂作用的几个特征，以及反应炔烃的电子性质。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE ADAMANTYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY
  申请人：Randox Laboratories Limited

  公开号：US20150346227A1

  公开（公告）日：2015-12-03

  An immunoassay method for detecting and determining adamantane substituted indazole and indole synthetic cannabinoids is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies.

  本文描述了一种用于检测和确定取代了金刚烷的吲唑和吲哚合成大麻素的免疫测定方法。还描述了用于实施该方法的组分，即抗体、检测试剂、固态设备和试剂盒，以及用于制备抗体的免疫原。
• Orally administrable formulation
  申请人：Greenspoon Allen

  公开号：US10456357B2

  公开（公告）日：2019-10-29

  An orally administrable chewing gum formulation is provided comprising a pharmaceutically acceptable gum base and particles of a pharmaceutical agent ranging in size from about 50 to about 2000 μm, wherein the formulation comprises about 0.5-30% by wt of the pharmaceutical agent particles. A liquid formulation comprising particles of a pharmaceutical agent is also provided.

  本发明提供了一种可口服的口香糖配方，包括药学上可接受的口香糖基质和粒径在约 50 至约 2000 μm 之间的药剂颗粒，其中该配方包含约 0.5-30% （重量百分比）的药剂颗粒。还提供了一种包含药剂颗粒的液体制剂。
• Pharmaceutical compositions containing cannabis, uses thereof and methods for improving sleep quality
  申请人：Exzell Pharma Inc.

  公开号：US10561694B2

  公开（公告）日：2020-02-18

  A pharmaceutical composition containing cannabis for improving the quality of sleep in a patient is provided. Also provided are a use of the pharmaceutical composition for improving the quality of sleep in a patient, and methods for improving the quality of sleep. The pharmaceutical composition preferably includes a combination of therapeutically effective amounts of one or more of the following medicinal ingredients: cannabis, and/or an herb.

  提供了一种含有大麻的药物组合物，用于改善患者的睡眠质量。还提供了该药物组合物改善患者睡眠质量的用途，以及改善睡眠质量的方法。药物组合物优选包括治疗有效量的一种或多种以下药用成分的组合：大麻和/或草药。
• Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue
  申请人：Exzell Pharma Inc.

  公开号：US10568920B2

  公开（公告）日：2020-02-25

  A pharmaceutical composition containing cannabis for increasing energy levels and/or alleviating fatigue in a patient. Also provided are a use of the pharmaceutical composition for increasing energy levels and/or alleviating fatigue in a patient, and methods for increasing energy levels and/or alleviating fatigue. The pharmaceutical composition preferably includes a combination of therapeutically effective amounts of one or more of the following medicinal ingredients: cannabis, an herb, vitamins, and/or fructose.

  一种含有大麻的药物组合物，用于提高患者的能量水平和/或缓解疲劳。还提供了该药物组合物用于提高患者能量水平和/或缓解疲劳的用途，以及提高能量水平和/或缓解疲劳的方法。药物组合物最好包括治疗有效量的以下一种或多种药用成分的组合：大麻、草药、维生素和/或果糖。